Related Experiment Video

Updated: Jun 11, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual

Melissa Paoloni1, Susan Lana, Douglas Thamm

  • 1Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. paolonim@mail.nih.gov

Veterinary Journal (London, England : 1997)
|July 13, 2010
PubMed

Insights

The National Cancer Institute-Comparative Oncology Trials Consortium (NCI-COTC) established a Pharmacodynamic Core (PD Core) to standardize drug evaluation in canine cancer. This infrastructure supports developing novel cancer drugs for both human and animal patients.

Area of Science:

  • Comparative oncology
  • Veterinary medicine
  • Translational cancer research

Background:

  • Novel drug development for human cancer requires robust evaluation methods.
  • Veterinary clinical trials necessitate specialized infrastructure for assessing drug efficacy and toxicity.
  • Pharmacokinetic and pharmacodynamic endpoints are crucial for understanding drug activity.

Purpose of the Study:

  • To establish a centralized laboratory infrastructure for uniform analysis of pharmacodynamic endpoints in veterinary clinical trials.
  • To support the National Cancer Institute-Comparative Oncology Trials Consortium (NCI-COTC) in evaluating novel drugs and biologics in dogs with cancer.
  • To facilitate veterinary biomarker validation.

Main Methods:

  • Establishment of the COTC Pharmacodynamic Core (PD Core) as a virtual laboratory.
  • Leveraging the expertise of the NCI-COTC investigator community.
  • Developing and executing quality-controlled assays for tissue and fluid endpoints.

Main Results:

  • The PD Core provides uniform end-point analysis for comparative oncology trials.
  • It addresses the need for centralized, quality-controlled assay development and execution.
  • Veterinary biomarker validation is a secondary outcome of the PD Core's efforts.

Conclusions:

  • The PD Core represents a successful infrastructure model within the veterinary research community.
  • This initiative aligns with technological advancements to improve cancer treatment for humans and animals.
  • The established infrastructure enhances the development of novel cancer therapeutics through comparative oncology.

More Related Videos

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

Creation and Maintenance of a Living Biobank - How We Do It13:08

Creation and Maintenance of a Living Biobank - How We Do It

Published on: April 10, 2021

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...